Erratum to the association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer

Editorial Office

Erratum to: J Thorac Dis 2021;13:3126-36

In the article (1) titled "the association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer" published in *Journal of Thoracic Disease* (J Thorac Dis 2021;13:3126-36. doi: 10.21037/jtd-21-755), there were some errors in the Results section.

(I) There is a typo in a confidence interval (CI) value.

Original sentence: The median PFS of patients with the G allele was 18.9 months (95% CI: 13.960–24.780), which was significantly higher than that of patients with the A allele (11.3 months, 95% CI: 8.655–14.005); the difference between the two groups was statistically significant (P=0.040).

Corrected sentence: The median PFS of patients with the G allele was 18.9 months (95% CI: 13.960–23.780), which was significantly higher than that of patients with the A allele (11.3 months, 95% CI: 8.655–14.005); the difference between the two groups was statistically significant (P=0.040).

(II) There were errors in *Table 3*. The corrected version of *Table 3* is included below.

Table 3 Association between the ERCC1/2 gene polymorphisms and prognosis in 87 NSCLC patients who received definitive radiotherapy

Gene	MST (months)	95% CI	P	Median PFS (months)	95% CI	P
rs11615						
AA	6.77	0–14.05	0.000	5.13	0–15.13	0.019
AG	19.77	11.14–28.40		11.33	5.76–16.91	
GG	30.90	12.83–48.97		18.87	13.96–23.78	
A allele	16.17	9.10–23.24	0.003	11.33	8.66–14.01	0.040
G allele	30.90	12.83–48.97		18.87	13.96–23.78	
rs3212961						
GG	24.77	4.75–44.79	0.735	11.53	6.41–16.66	0.910
GT	23.97	15.75–32.19		18.07	12.67–23.47	
TT	24.93	9.37–40.49		11.60	5.28–17.92	

Table 3 (*continued*)

Table 3 (*continued*)

Gene	MST (months)	95% CI	P	Median PFS (months)	95% CI	P
G allele	24.93	18.95–30.91	0.441	16.17	11.84–20.50	0.897
T allele	24.77	4.75–44.79		11.53	6.41–16.66	
rs3212986						
AA	71.13	0–160.416	0.092	15.53	0–38.01	0.718
AC	29.10	18.92–39.28		18.70	11.91–25.49	
CC	21.53	12.97–30.09		14.67	8.85–20.49	
A allele	30.90	15.68–46.12	0.086	18.07	8.85–20.49	0.423
C allele	21.53	12.97–30.09		14.67	11.89–24.25	
rs13181						
TT	24.93	16.19–33.67	0.692	14.67	10.17–19.17	0.921
TG	24.77	12.67–36.87		19.07	9.96–28.19	
rs238406						
TT	16.17	0–36.26	0.686	11.33	8.92–13.74	0.143
TG	28.67	22.72–34.62		21.50	16.86–26.14	
GG	19.80	13.76–25.84		11.30	6.67–15.93	
T allele	26.83	21.44–32.22	0.562	16.83	12.16–21.50	0.097
G allele	19.80	13.76–25.84		11.30	6.67–15.93	
rs1799793						
CC	25.40	18.74–32.05	0.222	15.53	11.79–19.27	0.411
CT	19.07	10.48–27.66		16.13	2.89–29.37	

NSCLC, non-small cell lung cancer; CI, confidence interval; MST, median overall survival time; PFS, progression-free survival.

Click here to view the updated version of the article.

References

1. Jiang C, Guo Y, Li Y, et al. The association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer. J Thorac Dis 2021;13:3126-36.